Global Psychiatric Digital Biomarkers Market Size To Exceed USD 3879.4 Million By 2033 | CAGR of 22.43%

Global Psychiatric Digital Biomarkers Market Size To Exceed USD 3879.4 Million by 2033

According to a research report published by Spherical Insights & Consulting, the Global Psychiatric Digital Biomarkers Market Size is Expected to Grow from USD 512.8 Million in 2023 to USD 3879.4 Million by 2033, at a CAGR of 22.43% during the forecast period 2023-2033. 

The global market for psychiatric digital biomarkers is centred on the creation, implementation, and application of digital technologies for measuring and analyzing physiological and behavioural data in order to diagnose, track, and treat mental illnesses. Many countries are investing in mental health management and the development of digital health technology. These projects assist the research and development of digital biomarkers. Governments are forming relationships with technology businesses to build innovative mental health management systems. The psychiatric digital biomarkers market provides numerous opportunities, particularly when combined with wearable technologies that allow for real-time monitoring of mental health problems. The growing use of telepsychiatry services allows for remote monitoring of samples, expanding access to tailored treatment. However, complications in the psychiatric digital biomarker business include varying regulatory criteria, high development costs, and little physician knowledge. Furthermore, uncertainty in patient engagement and potential resistance to adopting digital tools may impede general adoption, reducing the overall effectiveness of these novel solutions.

The wearable segment is expected to hold the largest share of the global psychiatric digital biomarkers market during the anticipation timeframe.       

Based on type, the global psychiatric digital biomarkers market is categorized as wearable, mobile based applications, and sensors. Among these, the wearable segment is expected to hold the largest share of the global psychiatric digital biomarkers market during the anticipation timeframe. Wearables can measure mental health markers continuously and in real time. These user-friendly devices promote regular use and smooth integration into health ecosystems.

The monitoring psychiatric digital biomarkers segment is expected to grow at the fastest CAGR during the anticipation timeframe.      

Based on the clinical practice, the global psychiatric digital biomarkers market is categorized as diagnostic psychiatric digital biomarkers, monitoring psychiatric digital biomarkers, predictive and prognostic psychiatric digital biomarkers. Among these, the monitoring psychiatric digital biomarkers segment is expected to grow at the fastest CAGR during the anticipation timeframe. The increased demand for real-time information on patients' mental health status. Monitoring psychiatric digital biomarker technologies offer continuous symptom tracking, allowing for faster treatments and more personalized therapy.

The pharmaceutical company’s segment is expected to hold the largest share of the global psychiatric digital biomarkers market during the anticipation timeframe.       

Based on end user, the global psychiatric digital biomarkers market is categorized as healthcare providers, pharmaceutical companies, and research institutions. Among these, the pharmaceutical company’s segment is expected to hold the largest share of the global psychiatric digital biomarkers market during the anticipation timeframe. pharmaceutical corporations to the psychiatric digital biomarkers market owing to their great usefulness in improving clinical trials, developing medications in a very productive method, and personalizing treatments connected to psychiatric diseases.

North America is projected to hold the largest share of the global psychiatric digital biomarkers market over the anticipation timeframe.

North America is projected to hold the largest share of the global psychiatric digital biomarkers market over the anticipation timeframe. North America's developed healthcare infrastructure allows for the rapid adoption of modern technologies. The region's high prevalence of mental health problems necessitates the development of appropriate monitoring and diagnosis procedures.

Europe is expected to grow at the fastest CAGR growth of the global psychiatric digital biomarkers market during the anticipation timeframe. Its strict regulatory system encourages innovation. The rising demand for high-quality mental health solutions demonstrates public awareness and the necessity of early intervention. Increased investment in digital health initiatives, combined with a focus on tailored care, is driving market expansion.

Major vendors in the global psychiatric digital biomarkers market are Empatica Inc., Vivo Sense, IXICO plc, Huma, Kintsugi Health, Sonde Health, Inc., Clario, Koneksa, Biogen Inc., BioSensics, iMediSync, BEATS Medical, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In March 2024, Biogen reported the initial findings of the RESPOND trial, which examined SPINRAZA in babies and toddlers with special needs after gene therapy. The majority of patients showed improved motor function and lower neurodegeneration markers.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global psychiatric digital biomarkers market based on the below-mentioned segments: 

Global Psychiatric Digital Biomarkers Market, By Type

• Wearable
• Mobile based Applications
• Sensors

Global Psychiatric Digital Biomarkers Market, By Clinical Practice

• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers

Global Psychiatric Digital Biomarkers Market, By End User

• Healthcare Provider
• Pharmaceutical Companies
• Research Institutions

Global Psychiatric Digital Biomarkers Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter